Sectors
BioTech, Health
Headquarters
Newark, CA, USA
CEO
Gilad Almogy
Ultima Genomics shares, as of April 21, 2025, are valued at a price per share implying an approximate +20.4% relative to the most recent significant secondary market activity in July 2024, according to PM Insights' market data. PM Insights uses a market-driven derived price methodology to determine Ultima Genomics's valuation when recent secondary market transactions are limited or unavailable, as is currently the case for Ultima Genomics.
Register today to view the full report, with more in-depth details and analytics
Latest funding round
XXXXX
XX-XX-XXXX
AV Implied Valuation
XXXXX
XX-XX-XXXX
Change since Last Round
XXXXX
XX-XX-XXXX
Secondary Activity
XXXXX
Business Partnerships
Targeted Impact
Who Will Benefit?
What Comes Next?
No items found.
.png)
Ultima Genomics shares, as of April 21, 2025, are valued at a price per share implying an approximate +20.4% relative to the most recent significant secondary market activity in July 2024, according to PM Insights' market data. PM Insights uses a market-driven derived price methodology to determine Ultima Genomics's valuation when recent secondary market transactions are limited or unavailable, as is currently the case for Ultima Genomics.
No items found.
No items found.
Ready to see it in action?
Schedule a demo with one of our experts
